. Author manuscript; available in PMC: 2013 Jul 1.

Published in final edited form as: Pharmacogenet Genomics. 2012 Jul;22(7):525–537. doi: 10.1097/FPC.0b013e32835366f6

Table 3.

Comparison of COX specific activities in PGHS-1 variants.

PGHS-1 variant	Heterozygosity^a	COX activity (relative to wildtype)
PGHS-1 variant	Heterozygosity^a	Present study^b	Lee et al. (2007)^c	Halushka et al. (2003)^d
Wildtype		1.00	1.00 ± 0.07	1.00 ± 0.07
W8R^e	0.091	ND	1.04 ± 0.10	0.84 ± 0.18
P17L	0.180	ND	1.13 ± 0.07	0.78 ± 0.10
R53H	0.004	0.46	0.35 ± 0.05^h	ND
R78W	ND^f	ND	0.36 ± 0.04^h	ND
R108Q	(0.04)^g	0.71	ND	ND
K185T	0.018	ND	0.59 ± 0.06^h	ND
G230S	0.005	ND	0.57 ± 0.04 ^h	ND
L237M	0.043	0.78	0.51 ± 0.03^h	ND
V481I	0.015	0.53	1.21 ± 0.10	ND

Current dbSNP value [13].

Normalized by Coomassie-stained protein density. Wildtype: 34 nmol O₂/min/μg PGHS-1 protein.

Normalized by immunoreactive protein density [15]. Wildtype: 20 μM O₂/min/mg total protein

Normalized to 5 × 10⁵ platelets [38]. Wildtype: 970 ng PGF2α/ml/30 s.

Sometimes listed as R8W.

Not determined.

Minor allele frequency [57].

P-value < 0.05 compared to wildtype.